A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
|
|
- Bryan Jackson
- 5 years ago
- Views:
Transcription
1 A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton University
2 Fong PC, et al. N Engl J Med. 2009;361(2): Phase I: Olaparib (2009)
3 Olaparib: Early Clinical Activity Phase I MTD 400 mg twice daily Expansion phase (N = 39 BRCA+) = responses Platinum-sensitive > resistant Platinum-Free Interval 24 CR/PR Sensitive Resistant Refractory SD >4 mo PD CR, complete response; PD, progressive disease; SD, stable disease Fong PC, et al. N Engl J Med. 2009;361(2):
4 Olaparib vs PLD: Study Design (2012) Primary objective: Compare efficacy (PFS) of 2 dose levels of olaparib (200 mg and 400 mg BID) with PLD Patients BRCA1/2 germline carriers with ovarian cancer Progressive or recurrent disease <12 months after previous platinum-based chemotherapy R 1:1:1 Olaparib 200 mg BID in 28-day cycles Olaparib 400 mg BID in 28-day cycles PLD 50 mg/m 2 IV every 4 weeks PD or withdrawal from treatment for other reason As above or max lifetime cumulative dose reached Stats: HR 0.55 (median PFS of 4 to 7.3 months) N planned: 90 (30/arm) Patients in PLD group were allowed to cross over to olaparib 400 mg BID on confirmed PD Kaye SB, et al. J Clin Oncol. 2012; 30(4):
5 Progression-Free Survival: Olaparib vs PLD Kaye SB, et al. J Clin Oncol. 2012; 30(4):
6 Study 42: Objective Response All patients 3 prior lines of therapy Anticipated response: <10% Kaufman B, et al. J Clin Oncol. 2015;33(3):
7 olaparib
8 EU Approval: Olaparib/Study 19 EMA Approval: December 16, 2014 Whole Population With HGSOC Subpopulation With BRCA Mutation P <.001 P <.0001 Ledermann J, et al. N Engl J Med. 2012;366(15): Ledermann J, et al. Lancet Oncol. 2014;15(8):
9 Olaparib in gbrca and BRCA wt Ovarian Cancer (2011) Ovarian gbrca Ovarian BRCA wt gbrca, platinum resistant or refractory gbrca, platinum sensitive BRCA wt, platinum resistant or refractory BRCA wt, platinum sensitive Gelmon KA, et al. Lancet. 2011; 12:
10 Why Would PARP Inhibitors Work in BRCA wt Patients? BRCA mut BRCA wt Hypothesis 1: Ovarian cancer patients with high genomic LOH suggesting BRCA-like signature will respond to PARPi BRCA wt Chromosome Number Hypothesis 2: Ovarian cancer patients who are biomarker negative (ie, with low genomic LOH) will not respond to PARPi
11 ARIEL2 (Rucaparib): PFS (2016) Median, months (95% CI) BRCA mut 12.8 ( ) BRCA wt /LOH high 5.7 ( ) BRCA wt /LOH low 5.2 ( ) Subgroup Comparison HR (95% CI) P BRCA mut vs BRCA wt /LOH low 0.27 ( ) BRCA wt /LOH high vs BRCA wt /LOH low 0.62 ( ) <.0001 = Coleman RL, et al. J Clin Oncol. 2016;34(15S): Abstract Swisher EM, et al. Lancet Oncol. 2017;18(1):75-87.
12 Rucaparib: Response in the FDA Label Outcome Investigator-assessed n = 106 Objective response rate (95% CI) 54% (44% - 64%) Complete response 9% Partial response 45% Median duration of response (95% CI) 9.2 months ( )
13
14 Switch Maintenance Induction therapy defined as platinum or platinum combination Clinical response is needed Measurable disease required at chemotherapy induction Partial response (PR) and CR are endpoints for randomization Usually a stratification variable Progression Chemo #2 M Chemo #3 M Chemo #4+ Death y
15 Platinum-Sensitive Relapse RCTs Maintenance After Chemotherapy Status Study 19 1 SOLO-2 2 NOVA 3 ARIEL3 4 Status Completed Completed Completed Completed Population HGSC gbrca mut II: Non-gBRCA I: gbrca mut HGSC 1. Ledermann J, et al. N Engl J Med. 2012;366: Pujade-Lauraine E, et al. Lancet Oncol. 2017;18(9): Mirza MR, et al. N Engl J Med. 2016;375: Coleman RL, et al. Lancet Sept 12. [Epub ahead of print] HGSC or endometrioid Design Phase II Phase III Phase III Phase III Regimen Olaparib vs placebo Olaparib vs placebo Niraparib vs placebo Rucaparib vs placebo Primary endpoint PFS PFS PFS PFS N (randomization) 265 (2:1) HGSC, high-grade serous carcinoma, RCT, randomized control trials 295 (2:1) 469 (2:1) 540 (2:1)
16 SOLO-2: Study Design (2017) Patients BRCA mut ovarian cancer 2 previous platinum regimens Last chemotherapy platinum-based in CR/PR R 2:1 n = 295 Olaparib 300 mg BID (n = 196) Placebo BID (n = 99) Primary endpoint: PFS by investigator Key secondary endpoints: PFS2 (investigator assessed) OS Safety Patient-reported outcomes Key sensitivity analysis: PFS by blinded-independent review (BICR) 1. Pujade-Lauraine E, et al. Lancet Oncol. 2017;18(9): Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy. 3. National Institutes of Health, Available at: Accessed October 12, 2017.
17 Platinum-Sensitive Relapse RCTs Maintenance After Chemotherapy: Olaparib Study Population N 19 (2012,2014,2016) Platinum-sensitive recurrent PFI, % Best platinum response, % CR PR SOLO-2 (2017) gbrca Study PFS PFS Other OS Notes 19 (2012,2014,2016) 8.4 vs 4.8 months 0.35 ( ) SOLO-2 (2017) Investigator (I ) 19.1 vs 5.5 months 0.30 ( ) PFI, platinum-free interval; BICR, blinded independent central review 1. Ledermann JA, et al. N Engl J Med. 2012;366: Ledermann JA, et al. Lancet Oncol. 2014;15(8): Ledermann JA, et al. J Clin Oncol. 2016;34(suppl): Abstract Pujade-Lauraine E, et al. Lancet Oncol. 2017;18(9): BRCA mut (N = 136) 11.2 vs 4.3 months 0.18 ( ) BICR 30.2 vs 5.5 months 0.25 ( ) 29.8 vs 27.8 months 0.73 ( ) P nominal = NS Immature (24% events) 2-year OS: 76.3% vs 74.0% BRCA status was post hoc PFS2 NR vs 18.4 months 0.5 ( )
18 NOVA Study Design (2016) Progression 6 months from last dose No measurable disease >2 cm; normal CA-125 or >90% decrease during last regimen (stable 7 days); PR or CR next to last/last platinum regimen Pre-Study Events Penultimate treatment course with a platinum-containing regimen Last treatment course with a platinumcontaining regimen Patient can be considered for the study and consented Study Events Non-gBRCA mut : sbrca mut, HRD+, HRD- Randomize patient within 8 wk of platinum-containing regimen based on centralized BRCA testing gbrca mut (n = 180) 2:1 Niraparib Placebo Disease progression: off study treatment Subsequent treatments Survival PRO/ imaging PRO Non-gBRCA mut (n = 289) 2:1 Niraparib Placebo Disease progression: off study treatment Subsequent treatments Survival National Institutes of Health, Available at: Accessed October 12, 2017.
19 Platinum-Sensitive Relapse RCTs Maintenance After Chemotherapy: Niraparib (2017) Study Population N PFI, % Best platinum response, % CR PR gbrca NOVA Non-gBRCA (sbrca, HRD- MyChoice wild type) Study Population PFS PFS Other OS Notes NOVA gbrca Non-gBRCA (sbrca, HRD- MyChoice wild type) PFI, platinum-free interval; BICR, blinded independent central review BICR (I ) 21 vs 5.5 months 0.27 ( ) BICR (I ) 9.3 vs 3.9 months 0.45 ( ) HRD+ (sbrca/hrd) 12.9 vs 3.8 months 0.38 ( ) Not yet mature Not yet mature Prior BEV: 25% HRD- only 6.9 vs 3.8 months 0.58 ( ) Mahner S, et al. Presented at: Society of Gynecologic Oncology Annual Meeting on Women s Cancer; March 12-15, 2017: National Harbor, Maryland.
20 NOVA-Niraparib: PFS (2017) gbrca mut Non-gBRCA mut Overall Non-gBRCA mut HRD+ 100 Niraparib Placebo 100 Niraparib Placebo 100 Niraparib Placebo PFS, % 50 PFS, % 50 PFS, % Time Since Randomization, mo Time Since Randomization, mo Time Since Randomization, mo HR 0.27, P<.0001 Median PFS, months Niraparib: 21.0 Placebo: 5.5 HR 0.45, P<.0001 Median PFS, months Niraparib: 9.3 Placebo: 3.9 HR 0.38, P<.0001 Median PFS, months Niraparib: 12.9 Placebo: 3.8 Mirza MR, et al. N Engl J Med. 2016;375:
21 First Approval of Switch Maintenance : Niraparib FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers [news release]. Silver Spring, MD: US Food & Drug Administration; March 27, 2017.
22 ARIEL3: Study Design Patient eligibility High-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal, or fallopian tube cancers 2 prior lines of platinum-based treatments No prior PARP inhibitors Sensitive to penultimate platinum Responding to most recent platinum (CR or PR)* Excludes patients without assessable disease following surgery before more recent platinumbased therapy ECOG PS 1 CA-125 within normal range No restriction on size of residual tumor Randomisation 2:1 Stratification HRR status by NGS mutation analysis Mutation in BRCA1, BRCA2, or non-brca HRR gene No mutation in BRCA or HRR gene Response to recent platinum CR PR Progression-free interval after penultimate platinum 6 to <12 months 12 months Rucaparib 600 mg BID n = 375 Placebo BID n = 189 *CR (defined by RECIST v1.1) or PR (defined by RECIST v1.1 and/or a GCIG CA-125 response [CA-125 within normal range]) maintained until entry to ARIEL3 ( 8 weeks of last dose of chemotherapy). ATM, ATR, ATRX, BARD1, BLM, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RPA1. HRR, homologous recombination repair; NGS, nextgeneration sequencing. Coleman RL, et al. Lancet Sept 12. [Epub ahead of print]
23 ARIEL3: Primary Endpoint and Step-Down Analysis Primary endpoint: Investigator-assessed PFS (per RECIST) BRCA mutant Germline or somatic BRCA mutation If significant* HRD Germline or somatic BRCA mutation + BRCA wild type/loh high ( 16% genomic LOH prespecified) BRCA mutation and LOH in tumor samples were measured using an NGS assay If significant* Intent to treat (ITT) (all comers) Germline or somatic BRCA mutation + BRCA wild type/loh high + BRCA wild type/loh low + BRCA wild type/ LOH indeterminate *Investigator-assessed PFS at a two-sided 0.05 significance level Visit cutoff date for all analyses: April 15, 2017 Coleman RL, et al. Lancet Sept 12. [Epub ahead of print]
24 ARIEL3: Investigator-Assessed PFS BRCA mutant ITT HRD Rucaparib (n = 130) Placebo (n = 66) Median (months) 95% CI HR, 0.23; 95% CI, ; P<.0001 Rucaparib (n = 375) Placebo (n = 189) Median (months) 95% CI HR, 0.36; 95% CI, ; P<.0001 Rucaparib (n = 236) Placebo (n = 118) Median (months) 95% CI HR, 0.32; 95% CI, ; P<.0001 At risk (events) Rucaparib 130 (0) 93 (23) 63 (46) 35 (58) 15 (64) 3 (67) 0 (67) Placebo 66 (0) 24 (37) 6 (53) 3 (55) 1 (56) 0 (56) Rucaparib, 48% censored Placebo, 15% censored At risk (events) Rucaparib 375 (0) 228 (111) 128 (186) 65 (217) 26 (226) 5 (234) 0 (234) Placebo 189 (0) 63 (114) 13 (160) 7 (164) 2 (167) 1 (167) 0 (167) Rucaparib, 38% censored Placebo, 12% censored At risk (events) Rucaparib 236 (0) 161 (55) 96 (104) 54 (122) 21 (129) 5 (134) 0 (134) Placebo 118 (0) 40 (68) 11 (95) 6 (98) 1 (101) 0 (101) Rucaparib, 43% censored Placebo, 14% censored Visit cutoff date: 15 April 2017 Coleman RL, et al. Lancet Sept 12. [Epub ahead of print]
25 ARIEL3: Exploratory Analysis: Investigator-Assessed ORR for Patients With Measurable Disease at Baseline BRCA mutant HRD ITT Rucaparib (n = 40) Placebo (n = 23) Rucaparib (n = 85) Placebo (n = 41) Rucaparib (n = 141) Placebo (n = 66) RECIST ORR, % (n) 37.5* (15) 8.7 (2) 27.1* (23) 7.3 (3) 18.4* (26) 7.6 (5) Complete response 17.5 (7) 0 (0) 11.8 (10) 0 (0) 7.1 (10) 1.5 (1) Partial response 20.0 (8) 8.7 (2) 15.3 (13) 7.3 (3) 11.3 (16) 6.1 (4) Stable disease 47.5 (19) 34.8 (8) 50.6 (43) 41.5 (17) 50.4 (71) 43.9 (29) Progressive disease 12.5 (5) 56.5 (13) 21.2 (18) 51.2 (21) 27.0 (38) 48.5 (32) Not evaluable 2.5 (1) 0 (0) 1.2 (1) 0 (0) 4.3 (6) 0 (0) *Cochran-Mantel-Haenszel P<.05 vs placebo Visit cutoff date: 15 April 2017 Coleman RL, et al. Lancet Sept 12. [Epub ahead of print]
26 Summary: Switch Maintenance Phase IIIs PFS (investigator review primary) Rucaparib Placebo HR P tbrca P<.0001 tbrca + HRD P<.0001 ITT P<.0001 PFS (BICR primary) Niraparib Placebo HR P tbrca P<.0001 tbrca + HRD NA NA NA All non-gbrca (sbrca + HRD + HRC) P<.001 ITT (FDA analysis) Not given PFS (investigator review - primary) Olaparib Placebo HR P gbrca P<.0001
27 The New Treatment Landscape in Advanced Ovarian Cancer Progression Death Diagnosis GOG 218 ICON7 NOVA SOLO-2; Study 19 ARIEL3 Symptoms IV Carboplatin + Paclitaxel + Bevacizumab Bevacizumab Maintenance Platinum Doublet PARPi Maintenance Staging Other Lines of Therapy and Clinical Trials Progression-Free Survival (12-28 months) Post Progression Survival (12-38 months)
28 Antiangiogenesis and PARP Inhibition: Rationale Chronic hypoxia induces downregulation of BRCA1 and RAD51, and decreases homologous recombination in cancer cells Anti-VEGF induces hypoxia in the tumor microenvironment, which contributes to genomic instability and increased sensitivity of cells to PARP inhibition Combination With VEGF Inhibitor Cediranib/Olaparib Significantly Increased PFS Compared to Olaparib Alone in Platinum-Sensitive Recurrent Ovarian Cancer Olaparib Cediranib/ olaparib PFS events Median PFS 9.0 months 17.7 months P =.005 HR 0.42 (95% CI: ) Tentori L, et al. Eur J Cancer. 2007;43(14): Liu J, et al. Lancet Oncol. 2014;15(11):
29 Combination With VEGF Inhibitor (US, Canada, Japan, Korea) NRG GY004 (NCT ) Olaparib vs Olaparib-Cediranib vs PCT Recurrent HGSC with PFI > 6 months (following most recent platinum) No more than 3 prior regimens (including primary therapy) RECIST measurable or evaluable disease with accessible tumor No prior PARPi therapy, prior bevacizumab permitted Stratify for BRCA status, number of prior treatment regimens Primary endpoint: PFS 85% power with HR Olaparib 300 mg BID R Cediranib 30 mg QD Olaparib 200 mg BID Open: FEB 2016 Status: Ongoing Accrual Target: 550 patients (135 BRCA1/2 +) Notes: Anticipate closure NOV2017 PCT, platinum-based chemotherapy Platinum-based combo* (IV) *Carboplatin + gemcitabine or paclitaxel or PLD Liu J, for NRG Oncology
30 Combination With VEGF Inhibitor (US, Canada) NRG GY005 (NCT ) Olaparib-Cediranib vs PCT Recurrent HGSC with PFI < 6 months (following most recent platinum) No more than 2 prior regimens (including primary therapy) RECIST measurable or evaluable disease, biopsy accessible No prior PARPi therapy, prior bevacizumab permitted Stratify for BRCA status, number of prior treatment regimens Primary endpoint: OS 90% power with HR 0.62 Phase II (n = 180) R Cediranib (PO) Olaparib (PO) Cediranib + olaparib (PO) Non-platinum chemo* (IV) Phase III (n = 280) R 1:1 Selected regimen (PO) Non-platinum chemo* (IV) * Weekly paclitaxel or PLD Open: FEB 2016 Status: Suspended for phase II interim analysis Target: 460 pts (135 BRCA1/2 +) Notes: Anticipate re-activation MAY2018 Lee J-M, for NRG Oncology
31 PAOLA-1 Study Design (NCT ) ARCAGY/GINECO Group sponsored study Combination With VEGF Inhibitor Phase III, randomized, double-blind, placebo-controlled, ex-us, multicenter study (maintenance setting) FIGO IIIb-IV High-grade serous or endometrioid, or epithelial nonmucinous ovarian, primary peritoneal, or fallopian tube cancer gbrcam Post 1 st line surgery and chemotherapy PR/CR 3 bevacizumab cycles N = 762 Randomization 2:1 Olaparib 300 mg tablets BID + bevacizumab 15 mg/kg Placebo tablets BID + bevacizumab 15 mg/kg Progression (up to 15 months) Follow up Primary endpoints Progression-free survival (up to 15 months) Key secondary endpoints Overall survival Time to earliest progression Second progression-free survival Time to first subsequent therapy or death Time to second subsequent therapy or death National Institutes of Health. Available at:
32 Rationale for PARPi With Immune Checkpoint Inhibitors Combination With IO Hypermutable states BRCA-mutant (somatic/germline) have high intrinsic LOH High-grade serous ovarian cancer has a hypermutable genotype in a proportion of patients PARPi can induce a hypermutable state All increase potential for neoantigens potentially amenable to PD-1/L1 targeting PARPi synergy may vary by PARPi and checkpoint inhibitor
33 PARPi Plus Checkpoint Inhibitors (in Maintenance) Combination With IO 1. Pfizer (avelumab and talazoparib) 2. AstraZeneca (olaparib and durvalumab) 3. Tesaro (niraparib and TSR-042) 4. AstraZeneca (olaparib) and Merck (pembrolizumab) partnership (July 27, 2017) 5. Clovis (rucaparib) and Bristol-Myers Squibb (nivolumab) partnership (July 31, 2017)
34 Summary and Conclusions 1. PARPi are a new therapeutic class of agents in treating ovarian cancer 2. Options for treatment AND switch maintenance 3. Biomarkers are key to patient selection and sequencing BRCA (molecular) HRD/LOA (molecular) Response to platinum (clinical) 4. Key challenges include the development of rational combinations
35 Thank You
36 The image part with relationship ID rid2 was not found in the file.
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Practice changing studies in Gynecological Cancer in 2017 Dr Susana Banerjee MBBS MA PhD FRCP Consultant Medical Oncologist and Research Lead Gynaecology Unit The Royal Marsden
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationClinical Data With PARP Inhibitors in Ovarian Cancer
Clinical Data With PARP Inhibitors in Ovarian Cancer Thomas J. Herzog, MD, FACOG, FACS Paul & Carolyn Flory Professor Clinical Director, University of CincinnaD Cancer InsDtute CincinnaD, OH Clinical Data
More informationCurrent GCIG Trials in Ovarian Cancer
Lead Grou p Log Current GCIG Trials in Ovarian Cancer Andres Poveda, MD GCIG Chair PARSGO Marrakech April 2018 History of GCIG Collaboration 1992 Collaboration on two studies of paclitaxel in ovarian cancer
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationNew Developments in Ovarian Cancer
New Developments in Ovarian Cancer Daniela Matei, MD Professor Gynecology Oncology Northwestern University Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Outline Recent and ongoing
More informationOvarian Cancer: It s Personal
Ovarian Cancer: It s Personal Review ovarian cancer: Incidence, origin, and management Discuss genetic testing: Who, why and what? Review current treatments for ovarian cancer Enhance understanding of
More informationClinical Development of Rucaparib
Clinical Development of Rucaparib Rucaparib is an investigational product and not approved by any health authority. Conclusions about efficacy and safety cannot be made Development of HRD/LOH Signature
More informationDemystifying Clinical Trials and some exciting new directions
Demystifying Clinical Trials and some exciting new directions Elise C. Kohn, MD Head, Gynecologic Cancer Therapeutics, Clinical Investigations Branch Cancer Therapy Evaluation Program National Cancer Institute
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationFILED: NEW YORK COUNTY CLERK 03/29/ :57 PM INDEX NO /2016 NYSCEF DOC. NO. 59 RECEIVED NYSCEF: 03/29/2017 EXHIBIT J
EXHIBIT J ASCO Clinical Data Update May 31, 2015 The Langham Hotel, Chicago Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer September 29, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer September 29, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More informationTargeting the DNA Damage Response: Lessons Learned and the Path Forward
Targeting the DNA Damage Response: Lessons Learned and the Path Forward Timothy A. Yap MBBS PhD MRCP BSc PgDip Associate Professor, Investigational Cancer Therapeutics and Thoracic/Head & Neck Medical
More informationDNA Damage Response analyst science event
DNA Damage Response analyst science event Mene Pangalos, EVP, Innovative Medicines & Early Development and Business Development Klaus Edvardsen, Vice President, Oncology Clinical, Global Medicines Development
More informationOptimizing DNA Damage Response- Targeting Therapies: Focus on Genetic Testing and Counseling
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationMerck Pfizer Alliance Strategy in gynecologic oncology
Merck Pfizer Alliance Strategy in gynecologic oncology Lenka Kostková, MD., PhD. GCIG CCRN Educational symposium and Clinical Trials Workshop Bucharest, February 3 rd, 2018 RO/AVEOV/1217/0001 Avelumab
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value. Evidence Report. August 30, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value Evidence Report August 30, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationGynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese. Milan - Italy
Gynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese Milan - Italy Mutations typically associated with ovarian carcinoma subtypes High-grade serous ovarian cancer TP53: encodes a protein that
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNordic Society of Gynaecological Oncology
Nordic Society of Gynaecological Oncology - from a Nordic interest group to a global leader in clinical trials Line Bjørge 14. mars 2017 I 1 Profile NSGO is a non-political, non-profit society Nordic platform
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value. Final Evidence Report. September 28, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value Final Evidence Report September 28, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationNuevas estrategias de tratamiento en tumores con mutaciones de BRCA
Nuevas estrategias de tratamiento en tumores con mutaciones de BRCA Emilio Alba UGCI Oncología Hospital Universitario Regional y Virgen de la Victoria Facultad de Medicina. Málaga IBIMA ÍNDICE DE LA PRESENTACIÓN
More informationCombining PARP Inhibition and Immunotherapy for Ovarian Cancer Oliver Dorigo, MD, PhD
Combining PARP Inhibition and Immunotherapy for Ovarian Cancer Oliver Dorigo, MD, PhD Director and Associate Professor, Division Gynecologic Oncology Director Mary Lake Polan Gynecologic Oncology Research
More informationStratification Age (<40 vs vs >50) Current (last dose <6 mths) combined oral contraceptive use (Yes vs No) BRCA status (BRCA1 vs BRCA2)
STICs and STONES: OV.24 A randomized phase II double-blind placebo-controlled trial of Acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with BRCA1/2 mutations/group name and number
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationCancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2
AWARD NUMBER: W81XWH-15-1-0084 TITLE: Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2 PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationHighlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women s Cancer
May 2017 Volume 15, Issue 5, Supplement 5 A SPECIAL MEETING REVIEW EDITION Highlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women s Cancer A Review of Selected
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationInitial Recommendation for Olaparib (Lynparza) for Ovarian Cancer perc Meeting: July 21, pcodr PAN-CANADIAN ONCOLOGY DRUG REVIEW 4
Overall, perc concluded that there may be a net clinical benefit with olaparib compared with placebo but the results are uncertain due to the limitations in the evidence from Study 19. perc discussed one
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationOverall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer
Overall survival results of ICON6: a trial of chemotherapy and in relapsed ovarian cancer Ledermann JA, Embleton AC, Perren T, Jayson GC, Rustin GJS, Kaye SB, Hirte HW, Oza AM, Vaughan MM, Friedlander
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More information